| |
The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV
|
| |
| |
Reported by Jules Levin
Presented at the 19th International Symposium on Hepatitis C Virus and Related Viruses; Venice, Italy; October 5-9, 2012
J. P. Bilello, C. B. Dousson, C. Pierra, D. Surleraux, M. La Colla, C. Chapron, I. Serra, N. Golitsina, F. Danehy, M. Camire, B. Hernandez-Santiago, J. F. McCarville, S. Bhadresa, X.R. Pan-Zhou, L. B. Lallos, H. Rashidzadeh, K. Gupta, M. Seifer, R. Rush and D. N. Standring
Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France.
|
|
| |
| |
|
|
|
